BERNARDSVILLE, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Anima Biotech, the leader in the discovery of small molecule drugs that control mRNA translation, today announced the company will present at the 22nd Annual BIO CEO & Investor Conference, taking place in New York, Feb. 10 – 11, 2020.
Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, will provide an overview of the company’s business, technology and partnering activities and will be available for questions and one-on-one meetings with attendees registered for the conference.
Details regarding the company’s presentation are as follows:
Event: 22nd Annual BIO CEO & Investor Conference
Date: Monday, Feb. 10, 2020
Time: 11 a.m. EST
Floor: Fourth Floor
Room: Brecht
Venue: New York Marriott Marquis, 1535 Broadway, New York
About Anima Biotech
Anima Biotech is advancing its Translation Control Platform, the first and only platform for the discovery of small molecule drugs that control mRNA translation as a new strategy against many diseases. With novel biology that monitors the translation of proteins and proprietary cloud-based analysis software, we identify drug candidates that modulate a target protein’s production. We develop a pipeline across therapeutic areas and partner with Pharma for their targets including our $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Our approach was further validated with 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations. To learn more about us, visit https://www.animabiotech.com
Media Contact:
Andrew Mielach
LifeSci Communications
+1.646.876.5868
amielach@lifescicomms.com